In September 2016, Smith donated $7 million to fund the development of an ALS and movement disorders clinic and neuroscience institute at Holy Cross Hospital, which work closely with Mass General clinicians and researchers.
Departments, Centers, & Programs:
15 Parkman Street
Boston, MA 02114-3117
- MD, Harvard Medical School
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Neurology, American Board of Psychiatry and Neurology
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
My research activities are dedicated to the study and treatment of patients with Amyotrophic Lateral Sclerosis (ALS) and other neurological disorders. As Director of the MGH Neurological Clinical Research Institute and the Principal Investigator for the NINDS supported NeuroNEXT Clinical Coordinating center (www.neuronext.org), I design clinical trials to evaluate the safety and effectiveness of therapies that have shown promise in preclinical studies. In ALS, I co-founded an international consortium to test novel therapies in ALS, the Northeast ALS (NEALS) consortium. The NEALS consortium consists of over 128 clinical sites in the United States and Canada dedicated to performing joint academic led clinical trials in ALS.. We are leading several new trials in ALS. There is a critical need in neurology for highly trained clinical investigators who work collaboratively with basic scientists to develop new therapeutic strategies.
In 2019 we launched the Sean M. Healey & AMG Center for ALS at Mass General. This new Center is dedicated to accelerating therapy development and access to treatments for people with ALS. We are launching the first Platform Trial initiative in ALS where several treatments will be tested in one platform approach. This groundbreaking initiative will cut in half the time to develop treatments, increase by 67% ability of people to receive active treatment and cut costs of drug development by 33%. This approach, already successful in oncology, will revolutionize how treatments are developed in ALS. The Healey Center bring collaborators from around the world to work together to find treatments for people with ALS.
- Press Release
- Dec | 6 | 2019
Inaugural Mass General Hospital HEALEY Center International Prize for Innovation in ALS Awarded at 2019 MND Meeting in Perth, Australia
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital awarded the inaugural annual Healey Center International Prize for Innovation in Amyotrophic Lateral Sclerosis (ALS) to the team that brought to trial the first antisense oligonucleotide (ASO) therapy for ALS.
- Nov | 14 | 2018
Episode #14 of the Charged Podcast.
- Nov | 21 | 2019
Congratulations to Merit Cudkowicz, MD, MSc, Director of the Sean M. Healey and AMG Center for ALS and Chief of Neurology at Mass General, who presented “A Powerful Promise,” a keynote speech at Accelerating Transformation, the 2019 Press Ganey National Client & Executive Leadership Conference.
- Jul | 10 | 2017
Mass General patient and Florida resident brings ALS care to his home state through gift.
- May | 16 | 2019
Doctors have struggled for years to find an effective treatment for amyotrophic lateral sclerosis (ALS), in part because it varies greatly from patient to patient in terms of how quickly it progresses and the age of onset.